Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution

Sun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It also offers diversification into new segments like women's health and biosimilars. The acquisition is expected to strengthen Sun Pharma's position for future growth. Managing integration and debt will be key.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVzPnCv
via IFTTT